Pere Domingo
Overview
Explore the profile of Pere Domingo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
367
Citations
4693
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bailon L, Molto J, Curran A, Cadinanos J, Carlos Lopez Bernaldo de Quiros J, de Los Santos I, et al.
Nat Commun
. 2025 Mar;
16(1):2146.
PMID: 40038256
Building on results from the AELIX-002 trial with HIVACAT T-cell immunogen (HTI)-based vaccines, the AELIX-003 (NCT04364035) trial tested the safety of the combination of ChAdOx1.HTI (C) and MVA.HTI (M), with...
2.
Bruguera A, Nomah D, Moreno-Fornes S, Martinez E, Negredo E, Tiraboschi J, et al.
AIDS
. 2024 Dec;
39(1):64-74.
PMID: 39639721
Objective: With HIV now a chronic condition and an aging population, understanding the evolving profiles of older people with HIV (PWH) is crucial. In this longitudinal study, we examined changes...
3.
Suades R, Greco M, Padro T, de Santisteban V, Domingo P, Benincasa G, et al.
Eur J Clin Invest
. 2024 Nov;
55(2):e14354.
PMID: 39548690
Background: The global pandemic of coronavirus disease 2019 (COVID-19) represented a major public health concern. Growing evidence shows that plasma of COVID-19 patients contains large numbers of circulating extracellular vesicles...
4.
Grunden N, Calabria M, Garcia-Sanchez C, Pons C, Arroyo J, Gomez-Anson B, et al.
PLoS One
. 2024 Aug;
19(8):e0302415.
PMID: 39116061
Cognitive difficulties are reported as lasting sequelae within post COVID-19 condition. However, the chronicity of these difficulties and related factors of fatigue, mood, and perceived health have yet to be...
5.
Llibre J, Revollo B, Aceiton J, Diaz Y, Domingo P, Burgos J, et al.
Lancet HIV
. 2024 Aug;
11(9):e598-e606.
PMID: 39102835
Background: People with HIV have a substantially higher risk of anal cancer than the general population. We aimed to identify risk factors associated with the development of anal cancer among...
6.
Ambia J, Ingle S, McGinnis K, Pantazis N, Silverberg M, Wittkop L, et al.
Open Forum Infect Dis
. 2024 Jul;
11(7):ofae333.
PMID: 39015347
Background: Predicting cause-specific mortality among people with HIV (PWH) could facilitate targeted care to improve survival. We assessed discrimination of the Veterans Aging Cohort Study (VACS) Index 2.0 in predicting...
7.
Suades R, Greco M, Prieto P, Padro T, Devaux Y, Domingo P, et al.
J Extracell Vesicles
. 2024 Jul;
13(7):e12456.
PMID: 39007437
Coronavirus disease 2019 (COVID-19) has been a major public health burden. We hypothesised that circulating extracellular vesicles (cEVs), key players in health and disease, could trace the cell changes during...
8.
Nomah D, Jamarkattel S, Bruguera A, Moreno-Fornes S, Diaz Y, Alonso L, et al.
Open Forum Infect Dis
. 2024 Apr;
11(4):ofae132.
PMID: 38560603
Background: Effective antiretroviral therapy (ART) has substantially reduced acquired immunodeficiency syndrome (AIDS)-related deaths, shifting the focus to non-AIDS conditions in people living with human immunodeficiency virus (HIV) (PLWH). We examined...
9.
Berenguer J, Jarrin I, Bellon J, Diez C, Jimenez-Sousa M, Lopez J, et al.
J Infect Dis
. 2024 Apr;
230(2):421-425.
PMID: 38557859
We studied the association of mitochondrial DNA (mtDNA) haplogroups with weight and body mass index (BMI) gain at 96 weeks in 1019 treatment-naive persons with HIV (PWH) who initiated first-line...
10.
de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, et al.
J Antimicrob Chemother
. 2024 Mar;
79(5):1133-1141.
PMID: 38546974
Introduction: The DOLAM trial revealed that switching from triple antiretroviral therapy (three-drug regimen; 3DR) to dolutegravir plus lamivudine (two-drug regimen; 2DR) was virologically non-inferior to continuing 3DR after 48 weeks...